RASP:RUSRaspadskaya Analysis

Actavia Life Sciences (RASP) is trading at a minuscule $0.0005 per share with a market cap of only $385,905, reflecting an extremely thin market (average daily volume of 20 shares). The stock exhibits a bearish trend direction despite a technically bullish MACD signal, and its beta of 0.058 indicates near‑zero correlation with broader market moves. Financially, the company reports zero revenue, zero margins, and a negative book value per share (-$0.003), resulting in a negative price‑to‑book ratio (-0.166). The historic max drawdown of -87.5% underscores the severe downside risk that has already been realized. The Fear & Greed Index reads 89.86 (“Extreme Greed”), suggesting market participants may be over‑optimistic despite the lack of operating performance. Overall, the combination of negligible liquidity, absent earnings, and a steep historical decline points to a high‑risk speculative play rather than a solid investment opportunity.